HTI immunogen - Aelix Therapeutics

Drug Profile

HTI immunogen - Aelix Therapeutics

Alternative Names: DNA.HTI; HIV vaccine - Aelix Therapeutics; MVA.HTI

Latest Information Update: 11 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Aelix Therapeutics
  • Class AIDS vaccines; Epitopes; Peptide vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 06 Jul 2017 Aelix Therapeutics plans the AELIX-002 phase I trial for HIV infections in Spain (NCT03204617)
  • 01 Jul 2017 Phase-I clinical trials in HIV infections in Spain (Parenteral) (NCT03204617)
  • 07 Jan 2016 Preclinical trials in HIV infections in Spain (Parenteral) before January 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top